Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax

Detalles Bibliográficos
Autores principales: Perriello, Vincenzo Maria, Falini, Lorenza, Ruggeri, Loredana, Sorcini, Daniele, Ballanti, Stelvio, Flenghi, Leonardo, Baffa, Nicodemo, Covarelli, Piero, Sportoletti, Paolo, Pierini, Antonio, Falini, Brunangelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188502/
https://www.ncbi.nlm.nih.gov/pubmed/37206291
http://dx.doi.org/10.1002/jha2.655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188502/
https://www.ncbi.nlm.nih.gov/pubmed/37206291
http://dx.doi.org/10.1002/jha2.655

Ejemplares similares